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INTRODUCTION 
Eye is most interesting organ due to its drug disposition 
characteristics. Generally, topical application of drugs is 
the method of choice under most circumstances because of 
its convenience and safety for ophthalmic chemotherapy.1 
A significant challenge to the formulator is to circumvent 
(bypass) the protective barriers of the eye without causing 
permanent tissue damage.2 Development of newer, more 
sensitive diagnostic techniques and novel therapeutic 
agents continue to provide ocular delivery systems with 
high therapeutic efficacy. Conventional ophthalmic 
formulations like solution, suspension, and ointment have 
many disadvantages which result into poor bioavailability 
of drug in the ocular cavity.  
The specific aim of designing a therapeutic system is to 
achieve an optimal concentration of a drug at the active 
site for the appropriate duration. Ocular disposition and 
elimination of a therapeutic agent is dependent upon its 
physicochemical properties as well as the relevant ocular 
anatomy and physiology. A successful design of a drug 
delivery system, therefore, requires an integrated 
knowledge of the drug molecule and the constraints 
offered by the ocular route of administration.3The various 
approaches that have been attempted to increase the 
bioavailability and the duration of the therapeutic action of 
ocular drugs can be divided into two categories. The first 
one is based on the use of sustained drug delivery drugs. 
The second involves maximizing corneal drug absorption 
and minimizing precorneal drug loss.3 Ideal ophthalmic 
drug delivery must be able to sustain the drug release and 
to remain in the vicinity of front of the eye for prolong 
period of time. Consequently it is imperative to optimize 
ophthalmic drug delivery; one of the ways to do so is by 
addition of polymers of various grades, development of 
ocusert using erodible or non-erodible insert to prolong the 
precorneal drug retention.4 
 
The zero order kinetics5 characteristics a sustained release 
type of delivery system whereby the drug is held in a 
reservoir and is released into the tear film at constant rate 
to provide a constant concentration in the corner which 
provides greatly improved compliance. Ciprofloxacin 
ocuserts 6 were also prepared by using polymers. Hence, 
the present study aimed to prepare Ciprofloxacin 
hydrochloride ocuserts.  
MATERIALS AND METHODS: 
Ciprofloxacin Hydrochloride was obtained as gift sample 
from Dhana pharmaceuticals Pvt.   Ltd, Ambarnath, India.
 
Hydroxy Propyl Methyl Cellulose (E-50), Poly vinyl 
pyrrolidone (K-30), Poly vinyl alcohol, Poly ethylene 
glycol- 400, Glycerine  were purchased from SD Fine 
chemicals, Mumbai, India. All other reagents and solvent 
used were of analytical grade. Cellophane membrane and 
distilled water were the other materials used. 
Instruments used: 
UV-spectrophotometer (shimadzu lab.), Digital oven, 
Verinier calliper’s scale and desiccator (Bros scientifics 
limited) were the instruments used for this study. 
Method: 
Standard calibration curve: 
7
 
Accurately weighed 100 mg Ciprofloxacin Hydrochloride 
was dissolved in 0.1N HCl  in 100 ml calibrated flask to 
get the stock solution . From this stock solution aliquots of   
2, 4, 8, 10, 12, & 14 ml were withdrawn and further diluted 
to 100 ml with 0.02N HCl to obtain a suitable 
concentrations range. The absorbance of the solutions was 
measured at 280 nm by using UV spectrophotometer. A 
graph of Concentration vs. Absorbance was plotted. 
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Preparation of Ocusert: 
7 
Ciprofloxacin hydrochloride was accurately weighed and 
dissolved in distilled water. Pre-determined HPMC, PVA 
and PVP was weighed and dissolved in distilled water 
separately in beaker.  Then clear drug solution was poured 
into polymer solution with constant stirring to get a 
homogenous solution. Required amount of PEG-400 was 
added and mixed well. The resulting solution was casted 
over the petri plate surface.The method used here was 
solvent casting method.  
Table no.1 Composition of Ciprofloxacin ocular inserts 
Ingredients MHF1 MHF2 MHF3 MHF4 
Ciprofloxacin HCL 100 mg 100 mg 100 mg 100 mg 
Poly vinyl pyrrolidone (K-30) 400 mg 600 mg 400 mg 600 mg 
Hydroxy Propyl Methyl Cellulose (E-50) 600 mg 400 mg - - 
Poly vinyl alcohol  - - 600 mg 600 mg 
Poly ethylene glycol- 400  0.5 ml 0.5 ml 0.5 ml 0.5 ml 
Glycerine 25mg 25 mg 25mg 25mg 
 
EVALUATION OF OCUSERT: 
% Moisture absorption: 
7
 
It was carried out to check the physical stability or 
integrity at wet condition. The prepared ocusert was 
accurately weighed and placed in a dessicator containing 
aluminium chloride with 79.5% moisture and it was kept 
for 3 days. The ocusert was taken out and reweighed after 
3 days. The amount of moisture absorbed by the ocusert 
was calculated by using the following formula. 
% moisture absorption   =    Final weight –Initial weight x 
100 
                            Initial weight 
% Moisture loss: 
11
 
The prepared ocusert was initially weighed and kept in a 
dessicator containing fused anhydrous calcium chloride 
and it was kept for 3 days. The ocusert was taken out and 
reweighed after 3 days. The % of moisture loss was 
calculated by using the following formula. 
% moisture loss = Final weight –Initial weight   x 100 
Initial weight 
Uniformity of thickness: 
8
  
The thickness of the insert was determined using a Vernier 
caliper at five separate points of each insert. For each 
formulation, five randomly selected inserts were tested for 
their thickness. 
Uniformity of weight: 
9, 10
 
From each batch, five inserts were taken out and weighed 
individually using digital balance (Asco, India). The mean 
weight of the insert was noted. 
Drug content: 
11
 
Five films were taken from each batch and dissolved or 
crushed in 10 ml of 0.1N in a beaker and were filtered into 
25 ml volumetric flask and the volume was made up to the 
mark with buffer. 1 ml of the above sample was withdrawn 
and the absorbance was measured by UV 
spectrophotometer 280 nm after suitable dilutions. 
In vitro drug release studies: 
12, 13
 
The in vitro drug release from the different ocular insert 
was studied using the classical standard cylindrical tube 
fabricated in the laboratory (bi-chambered donor receptor 
compartment model). A simple modification of glass tube 
of 15 mm internal diameter and 100 mm height. The 
diffusion cell membrane (prehydrated cellophane) was tied 
to one end of open cylinder, which acted as a donor 
compartment. An ocular insert was placed inside this 
compartment. The diffusion cell membrane acted as 
corneal epithelium. The entire surface of the membrane 
was in contact with the receptor compartment comprising 
of 12 ml of isotonic phosphate buffer (pH 7.4) in a 100 ml 
beaker. The content of receptor compartment was stirred 
continuously using a magnetic stirrer and temperature was 
maintained at 37±0.5°C. At specific intervals of time, 1 ml 
aliquot of solution was withdrawn from the receptor 
compartment and replaced with fresh buffer solution. The 
aliquot was analyzed for the drug content using UV 
spectrophotometer at 280 nm after appropriate dilutions 
against reference using isotonic phosphate buffer pH 7.4 as 
blank. 
Results and Discussion:  
Uniformity of thickness 
The thickness of ocular inserts (MHF1 to MHF4) was 
found to be in range of 0.148 mm to 0.154 mm as shown in 
(Table 2). The measured thickness of all the four 
formulations ensured uniformity in thickness. 
Uniformity of weight 
 The weight ocular inserts were found to be in the range of 
12.61 to 12.95 mg (Table 2). The uniformity of the weights 
of the films indicates good distribution of the drug, 
polymer and plasticizer. 
Drug content 
For the various formulations (MHF1 to MHF4), drug 
content was found to vary between 0.969 mg to 0.988 mg 
(Table 2). The estimation of drug content was found to be 
almost same. 
% Moisture absorption: 
For the various formulations (MHF1 to MHF4), % 
Moisture absorption was found to vary between 31.95 to 
33.15 (Table 2). The % moisture absorption was more in 
formulation I. 
% Moisture loss: 
For the various formulations (MHF1 to MHF4), % 
Moisture loss was found to vary between 30.18 to 32.83 
(Table 2). % moisture loss was more in formulation IV.
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Table 2: Physicochemical characteristics of various batches of ocular inserts 
Formulation 
code 
Weight* 
(mg) 
Thickness* 
(mm) 
Drug content* 
(mg) 
Drug Content 
(%) 
% Moisture 
absorption 
% Moisture loss 
 
MHF1 12.71 0.148 0.980 98.00 33.15 30.18 
MHF2 12.95 0.162 0.988 98.80 32.44 30.32 
MHF3 12.61 0.165 0.978 97.80 32.11 31.67 
MHF4 12.76 0.154 0.969 96.90 31.95 32.83 
 
 
 
Figure 1: Standard calibration curve of ciprofloxacin 
Table 3: In-vitro drug release studies 
Time (hrs) Cumulative drug 
release( MHF1) 
Cumulative drug  
release (MHF2) 
Cumulative   drug 
release (MHF3) 
Cumulative   drug 
release (MHF4) 
1 12.32 14.22 11.90 11.14 
2 14.28 18.31 13.65 13.58 
3 16.28 19.2 16.72 14.92 
4 17.82 21.56 18.64 16.11 
5 19.20 24.32 20.73 18.57 
6 21.22 27.23 22.45 19.76 
7 24.55 29.76 24.22 20.11 
8 26.42 31.85 25.34 22.29 
9 27.65 33.22 26.62 24.64 
10 28.64 34.18 27.35 25.13 
11 30.10 37.12 28.12 25.93 
12 31.39 38.95 28.95 27.11 
 
 
Figure 2: In-vitro drug release rate of all formulation 
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The results indicate formulation II has better drug release 
through an artificial membrane over an extended period of 
12 hours. 
CONCLUSION 
Various batches of Ciprofloxacin ocular inserts were 
prepared by solvent casting method and characterized. The 
formulation (MHF2) containing HPMC and PVP as 
polymer satisfied required pharmaceutical characteristics 
of ocular inserts and was found promising. The 
Ciprofloxacin ocusert is bio-degradable and would be able 
to offer benefits such as i.e., increasing residence time, 
prolonging drug release, reducing frequency of 
administration, and there by may help to improve patient 
compliance. The results indicate formulation II has better 
drug release through an artificial membrane over an 
extended period of 12 hours. However, their potential to 
improve ocular bioavailability in humans needs to be 
investigated further.  
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